Accordingly, they reasoned that cancer cells expressing predominately ROR1V3 relative to ROR1 would predominately express cytoplasmic, and not surface, ROR1 that could react with anti-ROR1 mAbs by IHC. This evidence concerns the gene ROR1 and cancer.